Mechanism of Lingmao Formula in treatment of chronic hepatitis B based on network pharmacology and animal experiment

Lijie MA; Xiaojun ZHU; Jiacheng LIN; Fang WANG; Xuehua SUN; Yueqiu GAO

doi:10.3969/j.issn.1001-5256.2022.07.010

Volume 38 Issue 7

Jul. 2022

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(7): 1503-1508

PDF( 3685 KB)

Mechanism of Lingmao Formula in treatment of chronic hepatitis B based on network pharmacology and animal experiment

DOI: 10.3969/j.issn.1001-5256.2022.07.010

Lijie MA^{1, 2},
Xiaojun ZHU²,
Jiacheng LIN²,
Fang WANG²,
Xuehua SUN²,
Yueqiu GAO^{2
,
,
,}

1.
Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
2.
Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China

Research funding:

National Natural Science Foundation of China (81774256);

National Natural Science Foundation of China (81874436)

More Information

Corresponding author: GAO Yueqiu, gaoyueqiu@hotmail.com (ORCID: 0000-0001-7276-9810)
Received Date: 2021-10-29
Accepted Date: 2021-12-17
Published Date: 2022-07-20

Abstract

Abstract

Objective To investigate the association between Lingmao Formula and type Ⅰ interferon in the treatment of chronic hepatitis B. Methods TCMSP database was used to obtain the main active components of Lingmao Formula; Genecards database was used to obtain the targets of Lingmao Formula and chronic hepatitis B; Bioinformatics was used to obtain the intersection of drug targets and disease targets, plot Venn diagram, and perform GO enrichment analysis, and DAVID 6.8 was used for KEGG enrichment analysis; CytoScape 3.8.0 was used to obtain immune response-related pathways. A total of 30 specific pathogen-free male C57BL/6N mice were randomly divided into normal group, model group, and Lingmao Formula group, with 10 mice in each group. All mice except those in the normal group were used to establish a model of HBV replication in vivo by hydrodynamic transfection; the mice in Lingmao Formula group were given Lingmao Formula by gavage, twice a day for 3 days, and those in the model group and the normal group were given an equal volume of normal saline by gavage. Serum samples were collected after the experiment ended and ELISA was used to measure the changes in the levels of HBsAg, HBeAg, and type Ⅰ interferon. The independent samples t-test was used for comparison of continuous data between two groups, and one-way ANOVA combined with the least significant difference t-test was used for multiple comparisons between groups. Results Network pharmacology obtained 22 active components and 6059 action targets of Lingmao Formula, 481 targets associated with chronic hepatitis, and 387 drug-disease intersecting targets and proposed the hypothesis that Lingmao Formula participated in hepatitis B-related immune response by regulating type Ⅰ interferon. Animal experiments confirmed that compared with the model group, the Lingmao Formula group had significant reductions in HBsAg (t=2.227, P=0.043) and HBeAg (t=2.488, P=0.026), with significantly greater reductions in HBsAg (t=-4.603, P < 0.001) and HBeAg (t=-2.224, P=0.043); compared with the normal group, the model group had no significant changes in the levels of IFNα and IFNβ (P > 0.05), and the Lingmao Formula group had significant increases in the levels of IFNα and IFNβ (P < 0.001); compared with the model group, the Lingmao Formula group also had significant increases in the levels of IFNα and IFNβ (P < 0.001). Conclusion Lingmao Formula exerts an anti-HBV effect by regulating the secretion of type Ⅰ interferon.
- Hepatitis B, Chronic,
- Lingmao Formula,
- Network Pharmacology,
- Animal Experiment,
- Interferon Type Ⅰ

FullText(HTML)

References(16)

References

[1]	Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007. 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648- 2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
[2]	CHEN BW, ZHU XJ, ZHANG X, et al. Influence of virologic response on disease progression in patients with compensated hepatitis B cirrhosis[J]. J Clin Hepatol, 2021, 37(8): 1811-1816. DOI: 10.3969/j.issn.1001-5256.2021.08.014. 陈博武, 朱晓骏, 张鑫, 等. 病毒学应答状态对代偿期乙型肝炎肝硬化患者疾病进展的影响[J]. 临床肝胆病杂志, 2021, 37(8): 1811-1816. DOI: 10.3969/j.issn.1001-5256.2021.08.014.
[3]	WU L, ZHANG ZP, CAI WT, et al. Research progress on anti-hepatitis B virus activity and mechanisms of traditional Chinese medicine[J]. Chin Tradit Herb Drug, 2020, 51(24): 6367-6376. DOI: 10.7501/j.issn.0253-2670.2020.24.028. 伍磊, 张志鹏, 蔡文涛, 等. 中药抗乙肝病毒活性及作用机制的研究进展[J]. 中草药, 2020, 51(24): 6367-6376. DOI: 10.7501/j.issn.0253-2670.2020.24.028.
[4]	ZHU XJ, ZHANG X, ZHOU ZH, et al. The lingmao formula suppresses the replication of hepatitis B virus by enhancing innate immune response[J]. Chin J Integr Tradit West Med Liver Dis, 2018, 28(1): 33-36. DOI: 10.3969/j.issn.1005-0264.2018.01.012. 朱晓骏, 张鑫, 周振华, 等. 灵猫方通过增强天然免疫功能抑制乙型肝炎病毒复制的研究[J]. 中西医结合肝病杂志, 2018, 28(1): 33-36. DOI: 10.3969/j.issn.1005-0264.2018.01.012.
[5]	ZENG ZJ, LI M, SUN XH, et al. Effects of Lingmao forumla and its actions against hepatic fibrosis[J/CD]. Chin J Clinicians (Electronic Edition), 2012, 6(15): 4258-4262. DOI: 10.3877/cma.j.issn.1674-0785.2012.15.023. 曾震军, 李曼, 孙学华, 等. 中药灵猫方的抗肝纤维化作用及其机制[J/CD]. 中华临床医师杂志(电子版), 2012, 6(15): 4258-4262. DOI: 10.3877/cma.j.issn.1674-0785.2012.15.023.
[6]	ZHANG X, ZHANG XW, DING J, et al. Effects of Lingmao recipe and its single herb alcohol extract on the expression of hepatitis B surface antigen and e antigen in HepG2.2.15 cells[J]. Hebei J TCM, 2017, 39(5): 729-734. DOI: 10.3969/j.issn.1002-2619.2017.05.022. 张鑫, 张晞文, 丁俊, 等. 灵猫方及其单味药醇提物对HepG2.2.15细胞乙型肝炎表面抗原和乙型肝炎e抗原表达的影响[J]. 河北中医, 2017, 39(5): 729-734. DOI: 10.3969/j.issn.1002-2619.2017.05.022.
[7]	JIANG Y, GAO YQ, LI M, et al. Therapeutic effect of "Lingmao Decoction" combined with telbivudine in treating patients with chronic hepatitis B and the influence on the function of NK cells[J]. Acta Univ Tradit Med Sin Pharmacol Shanghai, 2017, 31(2): 16-21. DOI: 10.16306/j.1008-861x.2017.02.005. 江云, 高月求, 李曼, 等. 灵猫方联合替比夫定治疗慢性乙型肝炎患者的疗效及对NK细胞功能的影响[J]. 上海中医药大学学报, 2017, 31(2): 16-21. DOI: 10.16306/j.1008-861x.2017.02.005.
[8]	JIANG Y, GAO YQ, LI GY. Experimental study of Lingmao Formula on protecting liver and reducing enzyme in acute liver injury model[J]. Chin J Tradit Med Sci Technol, 2012, 19(5): 406-407, 384. DOI: 10.3969/j.issn.1005-7072.2012.05.014. 江云, 高月求, 李桂勇. 灵猫方对急性肝损伤模型保肝降酶作用的实验研究[J]. 中国中医药科技, 2012, 19(5): 406-407, 384. DOI: 10.3969/j.issn.1005-7072.2012.05.014.
[9]	RU J, LI P, WANG J, et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines[J]. J Cheminform, 2014, 6: 13. DOI: 10.1186/1758-2946-6-13.
[10]	LAN SH, TANG QY, LI NN, et al. Mechanism of action of Xiaochaihu decoction in the treatment of hepatitis B based on network pharmacology[J]. J Clin Hepatol, 2021, 37(10): 2308- 2315. DOI: 10.3969/j.issn.1001-5256.2021.10.010. 蓝绍航, 唐秋媛, 李娜娜, 等. 基于网络药理学研究小柴胡汤治疗乙型肝炎的作用机制[J]. 临床肝胆病杂志, 2021, 37(10) : 2308-2315. DOI: 10.3969/j.issn.1001-5256.2021.10.010.
[11]	YONEDA M, HYUN J, JAKUBSKI S, et al. Hepatitis B virus and DNA stimulation trigger a rapid innate immune response through NF-κB[J]. J Immunol, 2016, 197(2): 630-643. DOI: 10.4049/jimmunol.1502677.
[12]	Ll FL, HUA J, LU YP, et al. Research advances in innate immunity against hepatitis B virus[J]. J Clin Hepatol, 2016, 32(5): 992-996. DOI: 10.3969/j.issn.1001-5256.2016.05.044. 李凤莉, 华娟, 卢银平, 等. HBV天然免疫的研究进展[J]. 临床肝胆病杂志, 2016, 32(5): 992-996. DOI: 10.3969/j.issn.1001-5256.2016.05.044.
[13]	BREZGIN S, KOSTYUSHEVA A, BAYUROVA E, et al. Immunity and viral infections: Modulating antiviral response via CRISPR-Cas systems[J]. Viruses, 2021, 13(7): 1373. DOI: 10.3390/v13071373.
[14]	IVASHKIV LB, DONLIN LT. Regulation of type Ⅰ interferon responses[J]. Nat Rev Immunol, 2014, 14(1): 36-49. DOI: 10.1038/nri3581.
[15]	XU F, SONG H, XIAO Q, et al. Type Ⅲ interferon-induced CBFβ inhibits HBV replication by hijacking HBx[J]. Cell Mol Immunol, 2019, 16(4): 357-366. DOI: 10.1038/s41423-018-0006-2.
[16]	LUCIFORA J, XIA Y, REISINGER F, et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA[J]. Science, 2014, 343(6176): 1221-1228. DOI: 10.1126/science.1243462.

Relative Articles

[1]	Kuan LI, Huibin NING, Huiming JIN, Zhen PENG, Jia SHANG. Effect of pegylated interferon α-2b on serum HBsAg clearance rate in treatment of patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2023, 39(8): 1819-1824. doi: 10.3969/j.issn.1001-5256.2023.08.009
[2]	Peiyao FAN, Fuchuan WANG, Yinjie GAO, Zhiqiang XU, Yi DONG, Jianguo YAN, Lili CAO, Danni FENG, Yanwei ZHONG, Min ZHANG. Value of serum PreS1 in early prediction of HBsAg clearance after IFN-α treatment in children with HBeAg-positive chronic hepatitis B[J]. Journal of Clinical Hepatology, 2023, 39(8): 1825-1831. doi: 10.3969/j.issn.1001-5256.2023.08.010
[3]	Wei ZHU, Xiaoyong ZHANG, Daqian ZHANG, Jinlin HOU. Strategies and advances in targeting adaptive immunity to cure chronic hepatitis B[J]. Journal of Clinical Hepatology, 2021, 37(5): 1016-1021. doi: 10.3969/j.issn.1001-5256.2021.05.005
[4]	Hong ZHANG, Xiaoxue ZHU, Jiajia MAI, Hong CHEN, Jing ZHOU, Yue HU, Jia XU, Yanhua DING. Clinical studies of new antiviral drugs for chronic hepatitis B[J]. Journal of Clinical Hepatology, 2021, 37(5): 1006-1010. doi: 10.3969/j.issn.1001-5256.2021.05.003
[5]	Kaimin SONG, Jun LIU. Advances in the application of transient elastography in chronic hepatitis B[J]. Journal of Clinical Hepatology, 2021, 37(2): 419-424. doi: 10.3969/j.issn.1001-5256.2021.02.036
[6]	Xuefu CHEN, Dongjing ZHANG, Xiaodan LUO, Ren CHEN. Current status of the treatment of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2021, 37(5): 1011-1015. doi: 10.3969/j.issn.1001-5256.2021.05.004
[7]	Weili NIU, Yongsu WANG, Qingshan WU, Lin ZHANG, Zhongqin ZHANG, Xiaojun YANG, Xianbin ZHU, Wenqin XIAO, Mingping JI. A clinical study of clinical cure after the addition of interferon therapy in chronic hepatitis B patients with low-level HBsAg previously treated with nucleos(t)ide analogues[J]. Journal of Clinical Hepatology, 2021, 37(8): 1793-1797. doi: 10.3969/j.issn.1001-5256.2021.08.010
[8]	Tian ZHANG, Sijing JIA, Dongxue SUN, Fengxi LONG, Dongxin TANG, Zhu YANG. Mechanism of "Szechwan Chinaberry Fruit-Rhizoma Corydalis" drug combination in treatment of liver cancer based on network pharmacology[J]. Journal of Clinical Hepatology, 2021, 37(9): 2136-2143. doi: 10.3969/j.issn.1001-5256.2021.09.026
[9]	Tingting ZHANG, Jue ZHAO, Yan YANG, Yaojie KANG, Xuan WANG. Type 1 diabetes mellitus due to pegylated interferon treatment of chronic hepatitis B: A case report[J]. Journal of Clinical Hepatology, 2021, 37(8): 1905-1906. doi: 10.3969/j.issn.1001-5256.2021.08.031
[10]	Qiuluo CHENG, Liu LIU, Changchuan BAI, Qingwei CONG, Ying ZHU. Mechanism of action of five classic prescriptions in treatment of hepatocellular carcinoma based on network pharmacology[J]. Journal of Clinical Hepatology, 2021, 37(8): 1848-1855. doi: 10.3969/j.issn.1001-5256.2021.08.020
[11]	Shaohang LAN, Qiuyuan TANG, Nana LI, Ran TAO, Nansheng LIAO, Yinjie MENG, Cao HE, Dewen MAO. Mechanism of action of Xiaochaihu decoction in the treatment of hepatitis B based on network pharmacology[J]. Journal of Clinical Hepatology, 2021, 37(10): 2308-2315. doi: 10.3969/j.issn.1001-5256.2021.10.010
[12]	Le TIAN, Yinghang WANG, Zhi PAN. Mechanism of Xiaozheng Huoluo prescription in preventing liver fibrosis in rats via the ERK5 pathway: An analysis based on network pharmacology[J]. Journal of Clinical Hepatology, 2021, 37(3): 582-589. doi: 10.3969/j.issn.1001-5256.2021.03.016
[13]	Jingshu QI, Dabing PING, Xin SUN, Jingbo XUE, Yanyan TAO, Yuan PENG, Chenghai LIU. Mechanism of action of Fuzheng Huayu prescription in treatment of liver cancer based on network pharmacology[J]. Journal of Clinical Hepatology, 2021, 37(10): 2338-2342. doi: 10.3969/j.issn.1001-5256.2021.10.016
[14]	Li Jing, Mo JiaHao, Xu HongBin, Zhu JunXia, Shi PeiYu, Xing WanLi, Zhong Chong, Lin LiZhu. Mechanism of action of Sini powder in treatment of liver cancer based on network pharmacology and molecular docking[J]. Journal of Clinical Hepatology, 2020, 36(9): 1998-2004. doi: 10.3969/j.issn.1001-5256.2020.09.018
[15]	Mu LiYa, Tang XiuFen, Li ShuQin, Yu Dan, Sun YuanYuan, Zhao JinHua. Clinical effects of bone marrow stem cell transplantation through different approaches in mice with acute liver injury[J]. Journal of Clinical Hepatology, 2019, 35(1): 153-156. doi: 10.3969/j.issn.1001-5256.2019.01.029
[16]	Lu Xin, Liu Ying, Jia Lei, Kong LingYu, Liu DianQing. Role of D-bifunctional protein in promoting the growth of hepatocellular carcinoma in rats and nude mice[J]. Journal of Clinical Hepatology, 2019, 35(7): 1532-1535. doi: 10.3969/j.issn.1001-5256.2019.07.022
[17]	Huang HaiYan, Xin YongNing, Jiang Man, Jin WenWen, Jiang XiangJun, Xuan ShiYing. Research advances in animal models of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2014, 30(9): 948-953. doi: 10.3969/j.issn.1001-5256.2014.09.028

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(3) / Tables(4)

Get Citation

PDF

XML

Article Metrics

Article views (648) PDF downloads(70)

Mechanism of Lingmao Formula in treatment of chronic hepatitis B based on network pharmacology and animal experiment

DOI: 10.3969/j.issn.1001-5256.2022.07.010

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Mechanism of Lingmao Formula in treatment of chronic hepatitis B based on network pharmacology and animal experiment

DOI: 10.3969/j.issn.1001-5256.2022.07.010

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content